PrintThe Burrill Report
June 21, 2013
http://www.burrillreport.com/article-breakthrough_therapies.html
REGULATORY
Breakthrough Therapies
Experimental therapies granted breakthrough designation status from the U.S. Food and Drug Administration.[Please login to post comments]
- Biotech Industry Shatters Fundraising Records in 2014
Ongoing fight over drug pricing overshadows industry in the new year Read More - G. Steven Burrill Issues Annual Predictions for the Biotechnology Industry
Focus to shift from promise to execution in 2015 Read More - Actavis’ $66B Purchase of Allergan Continues Record Year of M&A; Transactions for Life Sciences
Increasingly Competitive Environment for Sought-After Assets Pushes Prices Higher, Says Burrill Media. Read More - AbbVie Terminates Shire Acquisition, But M&A; Activity Remains Brisk
Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media Read More - U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences Dealmaking
Nearly half of dollar volume of M&A; activity in 2014 involved inversions, says Burrill Media Read More - Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More
